Regulation of Papillomavirus-Induced Immortalization by EGF-Receptor Inhibition

通过 EGF 受体抑制调节乳头瘤病毒诱导的永生化

基本信息

  • 批准号:
    7919063
  • 负责人:
  • 金额:
    $ 7.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-08-01 至 2011-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Infection with a subset of human papillomaviruses (HPV) is the major risk factor for cervical cancer. The HPV E6 and E7 genes are selectively retained and expressed in most malignant tumors, and persistent infection with HPV and immortalization of cervical cells are important events in cervical carcinogenesis. The majority of HPV infections are eliminated by the host immune response. However, women with acquired immune deficiency syndrome (AIDS) develop persistent HPV infections that progress to cervical intraepithelial neoplasia or cancer. AIDS patients also respond poorly to conventional therapy and their disease is likely to recur. Thus, women with AIDS would benefit from chemoprevention or therapy targeted to molecular pathways that are important for cervical carcinogenesis. The epidermal growth factor receptor (EGF-R) is a relevant target. The EGF- R is over expressed in cervical dysplasias and carcinomas, and patients with high EGF-R levels in their tumor have a poor prognosis. Our preliminary results indicate that inhibition of the EGF-R blocks an important step in cervical carcinogenesis; immortalization of cervical cells by HPV-16. Our long term goal is to determine whether the EGF-R is an effective target for chemoprevention or therapy of cervical cancer in AIDS patients. The objectives of this proposal are to (1) confirm that EGF-R inhibition prevents immortalization of cervical cells by HPV-16, and (2) identify the mechanism by which immortalization is inhibited. We will examine these questions using cultures of human epithelial cells derived from the cervical transformation zone, the site where most cervical cancers originate. Experiments will use Erlotinib (Tarceva), a small molecule EGF-R tyrosine kinase inhibitor that has been approved for therapy of human cancer. Studies will determine whether Erlotinib prevents immortalization of normal cervical cells by HPV-16 or inhibits growth of cervical cancer cells. Experiments will also determine whether Erlotinib prevents immortalization by (1) increasing susceptibility of E6/E7-expressing cells to apoptosis, (2) stimulating premature senescence, or (3) decreasing expression of HPV-16 DNA. Our results will clarify how EGF-R inhibition targets a novel pathway that is potentially important for chemoprevention and therapy of cervical cancer. Women with AIDS are particularly susceptible to cervical cancer. They respond poorly to conventional therapy and their cancers are likely to recur. Our results describe a novel target for chemoprevention or chemotherapy of cervical cancer that is relevant to AIDS patients or immune suppressed individuals. This involves prevention of immortalization by papillomaviruses by inhibition of the epidermal growth factor receptor. Since drugs that inhibit this receptor have already been approved to treat lung and colorectal cancer, it is reasonable to test whether they also inhibit cervical carcinogenesis.
描述(由申请人提供):人乳头瘤病毒(HPV)亚群感染是宫颈癌的主要危险因素。HPV E6和E7基因在大多数恶性肿瘤中选择性保留和表达,HPV持续感染和宫颈细胞永生化是宫颈癌发生的重要事件。大多数HPV感染通过宿主免疫反应消除。然而,患有获得性免疫缺陷综合征(AIDS)的妇女发展为持续的HPV感染,其进展为宫颈上皮内瘤变或癌症。艾滋病患者对常规疗法的反应也很差,而且他们的疾病很可能复发。因此,艾滋病妇女将受益于针对宫颈癌发生重要分子途径的化学预防或治疗。表皮生长因子受体(EGF-R)是一个相关的目标。EGF-R在宫颈不典型增生和宫颈癌中过度表达,肿瘤中EGF-R水平高的患者预后不良。我们的初步结果表明,抑制EGF-R阻断了宫颈癌发生的重要步骤; HPV-16使宫颈细胞永生化。我们的长期目标是确定EGF-R是否是艾滋病患者宫颈癌化学预防或治疗的有效靶点。本提案的目的是(1)确认EGF-R抑制可防止HPV-16引起的宫颈细胞永生化,以及(2)确定永生化被抑制的机制。我们将使用来自宫颈转化区的人类上皮细胞培养物来研究这些问题,宫颈转化区是大多数宫颈癌的起源地。实验将使用Erlotinib(Tarceva),一种已被批准用于治疗人类癌症的小分子EGF-R酪氨酸激酶抑制剂。研究将确定厄洛替尼是否能阻止HPV-16对正常宫颈细胞的永生化或抑制宫颈癌细胞的生长。实验还将确定厄洛替尼是否通过(1)增加E6/E7表达细胞对凋亡的易感性,(2)刺激早衰,或(3)降低HPV-16 DNA的表达来防止永生化。我们的研究结果将阐明EGF-R抑制如何靶向一个新的途径,这对宫颈癌的化学预防和治疗具有潜在的重要意义。患有艾滋病的妇女特别容易患上宫颈癌。他们对常规治疗的反应很差,他们的癌症很可能复发。我们的研究结果描述了一种新的宫颈癌化学预防或化疗的目标,是相关的艾滋病患者或免疫抑制的个人。这涉及通过抑制表皮生长因子受体来预防乳头瘤病毒的永生化。由于抑制这种受体的药物已经被批准用于治疗肺癌和结直肠癌,因此测试它们是否也抑制宫颈癌发生是合理的。

项目成果

期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Ultrabright fluorescent mesoporous silica nanoparticles for prescreening of cervical cancer.
Human papillomavirus type 16 E6 and E 7 proteins alter NF-kB in cultured cervical epithelial cells and inhibition of NF-kB promotes cell growth and immortalization.
  • DOI:
    10.1016/j.virol.2011.12.023
  • 发表时间:
    2012-03-30
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Vandermark ER;Deluca KA;Gardner CR;Marker DF;Schreiner CN;Strickland DA;Wilton KM;Mondal S;Woodworth CD
  • 通讯作者:
    Woodworth CD
Physical labeling of papillomavirus-infected, immortal, and cancerous cervical epithelial cells reveal surface changes at immortal stage.
  • DOI:
    10.1007/s12013-012-9345-2
  • 发表时间:
    2012-06
  • 期刊:
  • 影响因子:
    2.6
  • 作者:
    Iyer, K. Swaminathan;Gaikwad, R. M.;Woodworth, C. D.;Volkov, D. O.;Sokolov, Igor
  • 通讯作者:
    Sokolov, Igor
Detection of cancerous cervical cells using physical adhesion of fluorescent silica particles and centripetal force.
  • DOI:
    10.1039/c0an00366b
  • 发表时间:
    2011-04-07
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Gaikwad RM;Dokukin ME;Iyer KS;Woodworth CD;Volkov DO;Sokolov I
  • 通讯作者:
    Sokolov I
Towards early detection of cervical cancer: Fractal dimension of AFM images of human cervical epithelial cells at different stages of progression to cancer.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CRAIG Duncan WOODWORTH其他文献

CRAIG Duncan WOODWORTH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CRAIG Duncan WOODWORTH', 18)}}的其他基金

Interaction of HPV with cells of the transformation zone
HPV 与转化区细胞的相互作用
  • 批准号:
    8433061
  • 财政年份:
    2013
  • 资助金额:
    $ 7.5万
  • 项目类别:
Regulation of Papillomavirus-Induced Immortalization by EGF-Receptor Inhibition
通过 EGF 受体抑制调节乳头瘤病毒诱导的永生化
  • 批准号:
    7228794
  • 财政年份:
    2007
  • 资助金额:
    $ 7.5万
  • 项目类别:
Regulation of Papillomavirus-Induced Immortalization by EGF-Receptor Inhibition
通过 EGF 受体抑制调节乳头瘤病毒诱导的永生化
  • 批准号:
    7497367
  • 财政年份:
    2007
  • 资助金额:
    $ 7.5万
  • 项目类别:
Activation of NF-kB by Human Papillomaviruses
人乳头瘤病毒对 NF-kB 的激活
  • 批准号:
    6752634
  • 财政年份:
    2004
  • 资助金额:
    $ 7.5万
  • 项目类别:
Activation of NF-kB by Human Papillomaviruses
人乳头瘤病毒对 NF-kB 的激活
  • 批准号:
    7032222
  • 财政年份:
    2004
  • 资助金额:
    $ 7.5万
  • 项目类别:
Activation of NF-kB by Human Papillomaviruses
人乳头瘤病毒对 NF-kB 的激活
  • 批准号:
    7054351
  • 财政年份:
    2004
  • 资助金额:
    $ 7.5万
  • 项目类别:
Activation of NF-kB by Human Papillomaviruses
人乳头瘤病毒对 NF-kB 的激活
  • 批准号:
    7225112
  • 财政年份:
    2004
  • 资助金额:
    $ 7.5万
  • 项目类别:
Activation of NF-kB by Human Papillomaviruses
人乳头瘤病毒对 NF-kB 的激活
  • 批准号:
    7059258
  • 财政年份:
    2004
  • 资助金额:
    $ 7.5万
  • 项目类别:

相似国自然基金

Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 批准年份:
    2020
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 批准年份:
    2017
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 批准年份:
    2016
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 批准年份:
    2014
  • 资助金额:
    73.0 万元
  • 项目类别:
    面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
  • 批准号:
    81301123
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
  • 批准号:
    81101529
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
  • 批准号:
    39500043
  • 批准年份:
    1995
  • 资助金额:
    9.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Spatial Restriction of Apoptotic Machinery during Neuronal Apoptosis and Pruning
神经元凋亡和修剪过程中凋亡机制的空间限制
  • 批准号:
    10596657
  • 财政年份:
    2021
  • 资助金额:
    $ 7.5万
  • 项目类别:
Spatial Restriction of Apoptotic Machinery during Neuronal Apoptosis and Pruning
神经元凋亡和修剪过程中凋亡机制的空间限制
  • 批准号:
    10417219
  • 财政年份:
    2021
  • 资助金额:
    $ 7.5万
  • 项目类别:
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
  • 批准号:
    441952-2013
  • 财政年份:
    2015
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
  • 批准号:
    441952-2013
  • 财政年份:
    2014
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Understanding the activation of pro-apoptotic Bcl-2 family proteins for the development of modulators of apoptosis
了解促凋亡 Bcl-2 家族蛋白的激活以开发凋亡调节剂
  • 批准号:
    nhmrc : 1059331
  • 财政年份:
    2014
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Project Grants
Examining the contribution of apoptosis repressor with caspase recruitment domain (ARC) to the anti-apoptotic effect of endurance training in skeletal muscle
检查具有半胱天冬酶募集结构域 (ARC) 的凋亡抑制因子对骨骼肌耐力训练的抗凋亡作用的贡献
  • 批准号:
    441952-2013
  • 财政年份:
    2013
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Postgraduate Scholarships - Doctoral
Apoptotic Osteocytes Promote Chondrocyte Apoptosis via Soluble Factors
凋亡骨细胞通过可溶性因子促进软骨细胞凋亡
  • 批准号:
    251802
  • 财政年份:
    2012
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Studentship Programs
Defining the mechanism(s) by which the cellular inhibitor of apoptosis protein 2 (cIAP2) contributes to early stage atherosclerosis development by directly promoting the participation of key apoptotic pathways within lesion-associated macrophages
确定凋亡蛋白细胞抑制剂 2 (cIAP2) 通过直接促进病变相关巨噬细胞内关键凋亡途径的参与来促进早期动脉粥样硬化发展的机制
  • 批准号:
    191299
  • 财政年份:
    2009
  • 资助金额:
    $ 7.5万
  • 项目类别:
    Operating Grants
ATP release during apoptosis and its relevance to apoptotic cell clearance
凋亡过程中 ATP 释放及其与凋亡细胞清除的相关性
  • 批准号:
    8075522
  • 财政年份:
    2009
  • 资助金额:
    $ 7.5万
  • 项目类别:
ATP release during apoptosis and its relevance to apoptotic cell clearance
凋亡过程中 ATP 释放及其与凋亡细胞清除的相关性
  • 批准号:
    7676912
  • 财政年份:
    2009
  • 资助金额:
    $ 7.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了